Instil Bio Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$1.17next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results and Corporate Update | 12 Nov 2026 |
| Q4 and Full Year 2026 Financial Results and Corporate Update | 25 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Total Cash, Cash Equivalents, Restricted Cash, and Marketable Securities Quarterly74.7MTarget: Sufficient to fund operations beyond 2027
Quarterly Research and Development (R&D) Expenses Quarterly700KTarget: Maintain low-overhead operating model
Quarterly General and Administrative (G&A) Expenses Quarterly5.3MTarget: Optimize administrative spend post-restructuring
Watch Items
- Execution of new in-licensing or acquisition transactionsTrigger: Announcement of a definitive agreement for a novel therapeutic candidateAction: Re-evaluate pipeline valuation, clinical development timelines, and cash runway impact
- Clinical progress of IMM2510/SYN-2510 in China by collaborator ImmuneOncoTrigger: Release of initial clinical data from Phase 1b/2 trials in front-line NSCLC or TNBCAction: Assess efficacy signals (ORR, PFS) and safety profile to validate the PD-L1xVEGF bispecific mechanism
- Strategic direction of legacy cell therapy assets (CoStAR platform / ITIL-306)Trigger: Initiation of dose expansion cohorts or investigator-initiated trials in ChinaAction: Monitor for potential non-dilutive funding or partnership opportunities to advance cell therapy programs
Research as of 19 Jun 2026